Proteona announces multiple ASH presentations highlighting novel gene signatures in hematological cancers identified using advanced single-cell biomarker discovery platform
Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology
SINGAPORE, 08 December 2021 - Proteona, a single-cell precision medicine company, today announced that three abstracts from the company and its collaborators have been accepted for presentation at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition to be held on December 11-14 in Atlanta, Georgia.
Two of the upcoming presentations, conducted in collaboration with Professor Chng Wee Joo (Director of the National University Cancer Institute, Singapore), identified novel biomarkers using Proteona’s ESCAPE™ and MapSuite™ platforms for single-cell multi-omic library generation and AI-assisted data analysis, respectively. In the first study on Acute Myeloid Leukemia (oral presentation #378), Proteona’s technology identified gene signatures from multiple dysregulated immune cell types that correlated with overall survival. In a second study on multiple myeloma (poster #2653), Proteona’s technology identified a gene signature in <1% of tumor microenvironment cells that correlated with progression-free survival in patients with the t(4:14) translocation.
In the third presentation (poster #2954), Proteona and its collaborators from Professor Limsoon Wong’s lab (National University of Singapore) will present MapBatch™, a novel machine-learning method for single-cell data batch correction that outperforms current approaches by retaining greater signal to noise.
“Alterations in the immune microenvironment play a key role in hematological cancer treatment response. Single-cell insights are critical to advance our understanding of how the microenvironment regulates response. Proteona's technology platform and expertise in developing single-cell gene signatures helped us identify biological insights that we could not have generated ourselves,” said Professor Chng. “We are in the process of validating the gene signatures identified and are excited to collaborate with Proteona on future projects in hematological cancer.”
“These studies demonstrate the value of Proteona’s single-cell technology platform to generate valuable insights for our research partners,” said Dr Andreas Schmidt, CEO of Proteona. “We aim to advance precision medicine in hematological and other cancers by developing industry-leading solutions for single-cell biomarker discovery, validation, and clinical use.”
December 12, 10:45 AM ET
Thomas Murphy Ballroom 3-4
December 12, 6-8 PM ET
December 12, 6-8 PM ET
For media queries, please contact:
Dr. Andreas Schmidt
Proteona Pte. Ltd. is a biomedical company in Singapore, Germany, and the US that is pioneering the use of single cell proteogenomics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona provides a comprehensive sample to answer service that enables users to phenotype cells using standard protein markers and gain a deeper understanding of cell activity based upon their gene expression profiles. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR).